Artiva Biotherapeutics (NASDAQ:ARTV) Insider Sells $63,403.37 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 7,037 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $63,403.37. Following the transaction, the insider owned 144,963 shares of the company’s stock, valued at $1,306,116.63. The trade was a 4.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Down 7.3%

ARTV traded down $0.67 during trading hours on Tuesday, hitting $8.55. 844,679 shares of the company’s stock were exchanged, compared to its average volume of 581,930. Artiva Biotherapeutics, Inc. has a 1-year low of $1.47 and a 1-year high of $14.53. The stock’s 50-day moving average is $8.32 and its two-hundred day moving average is $5.65. The stock has a market cap of $211.36 million, a price-to-earnings ratio of -2.42 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, equities research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on ARTV. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Needham & Company LLC increased their target price on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Finally, Wedbush increased their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC lifted its stake in Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after acquiring an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after acquiring an additional 37,053 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth about $341,000. Finally, Jane Street Group LLC acquired a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth about $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.